What is the current evidence on the efficacy, recommended dosing, and safety of oral caprylic acid (medium‑chain fatty acid C8) for treating Candida overgrowth, metabolic disorders, and mild cognitive impairment?

Caprylic Acid for Candida, Metabolic Disorders, and Cognitive Impairment

Caprylic acid is not recommended as a treatment for Candida infections, as it has no role in evidence-based clinical guidelines; established antifungal agents such as fluconazole, echinocandins, or amphotericin B should be used instead.

Candida Overgrowth Treatment

Guideline-Based Standard of Care

The Infectious Diseases Society of America provides clear treatment algorithms that do not include caprylic acid 1, 2:

For vulvovaginal candidiasis:

• Oral fluconazole 150 mg single dose is first-line 2
• Topical azoles (clotrimazole or miconazole) for 1-7 days are equally effective alternatives 2

For oropharyngeal candidiasis:

• Mild disease: Clotrimazole troches 10 mg 5 times daily for 7-14 days 2
• Moderate-to-severe disease: Oral fluconazole 100-200 mg daily for 7-14 days 2

For invasive candidiasis/candidemia:

• Echinocandins (caspofungin 70 mg loading, then 50 mg daily; micafungin 100 mg daily; or anidulafungin 200 mg loading, then 100 mg daily) are preferred first-line agents 1, 2
• Fluconazole 800 mg loading dose, then 400 mg daily is acceptable only for hemodynamically stable patients without recent azole exposure 1, 2
• Central venous catheter removal is strongly recommended when feasible 1

Research on Caprylic Acid: Laboratory Findings Only

While laboratory studies show caprylic acid has anti-Candida properties in vitro, these findings have not translated to clinical practice 3, 4, 5, 6:

• Caprylic acid inhibits Candida morphogenesis, adhesion, and biofilm formation in laboratory settings 5
• In vitro studies demonstrate inhibition of virulence factors including phospholipase and proteinase production 4
• A murine oral candidiasis model showed symptom improvement with capric acid (not caprylic acid) at concentrations ≥48.8 µM administered three times 6
• A fatty acid derivative showed membrane disruption and potentiation of azoles in laboratory studies 3

Critical caveat: None of these studies provide human clinical trial data, recommended dosing for humans, or safety profiles for therapeutic use. The concentrations used in laboratory studies cannot be extrapolated to oral human dosing 3, 4, 5, 6.

Metabolic Disorders

No evidence was provided regarding caprylic acid for metabolic disorders. Standard medical management of specific metabolic conditions should be followed based on established clinical guidelines.

Mild Cognitive Impairment

Observational Data Only

One observational study from the Alzheimer's Disease Neuroimaging Initiative cohort examined plasma caprylic acid levels and cognitive outcomes 7:

• Higher baseline plasma C8:0 levels showed borderline inverse association with incident MCI risk among cognitively normal participants 7
• Significant inverse associations were found only in specific subgroups: females [OR 0.60 (0.38-0.94)], those with ≥1 cardiometabolic disease [OR 0.75 (0.58-0.98)], one APOE ε4 allele [OR 0.43 (0.21-0.89)], or higher ADAS-Cog 13 scores [OR 0.69 (0.50-0.97)] 7
• This was an association study measuring endogenous plasma levels, not an intervention trial 7

Critical limitations: This observational study cannot establish causation, provides no dosing recommendations, and does not demonstrate that oral caprylic acid supplementation prevents MCI. No clinical trials have tested caprylic acid supplementation for cognitive outcomes 7.

Clinical Bottom Line

For Candida infections: Use guideline-recommended antifungals (fluconazole, echinocandins, or amphotericin B depending on infection site and severity) rather than unproven supplements 1, 2. Caprylic acid lacks clinical trial evidence, established dosing, or safety data for human Candida infections despite promising laboratory findings 3, 4, 5, 6.

For cognitive impairment: No intervention trials support caprylic acid supplementation for MCI prevention or treatment. The single observational study showing associations between endogenous plasma levels and MCI risk cannot guide clinical recommendations 7.